Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bioventus (BVS) Revenue (2020 - 2025)

Bioventus' Revenue history spans 6 years, with the latest figure at $157.9 million for Q4 2025.

  • For Q4 2025, Revenue rose 2.77% year-over-year to $157.9 million; the TTM value through Dec 2025 reached $568.1 million, down 0.91%, while the annual FY2025 figure was $568.1 million, 0.91% down from the prior year.
  • Revenue reached $157.9 million in Q4 2025 per BVS's latest filing, up from $138.7 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $157.9 million in Q4 2025 to a low of $81.8 million in Q2 2021.
  • Average Revenue over 5 years is $129.8 million, with a median of $129.9 million recorded in 2021.
  • Peak YoY movement for Revenue: skyrocketed 89.28% in 2021, then decreased 6.12% in 2023.
  • A 5-year view of Revenue shows it stood at $130.4 million in 2021, then dropped by 3.51% to $125.8 million in 2022, then grew by 7.62% to $135.4 million in 2023, then rose by 13.45% to $153.6 million in 2024, then rose by 2.77% to $157.9 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Revenue are $157.9 million (Q4 2025), $138.7 million (Q3 2025), and $147.7 million (Q2 2025).